Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q3 2023 · 10-Q
Revenue$2.94M$2.94M+1.4% vs Q3 2022 Net Income-$1.94M-$1.94MN/M vs Q3 2022 EPS Diluted-$0.62-$0.62N/M vs Q3 2022 Gross Profit$831,000−30.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$348,000N/M Free Cash Flowderived-$379,000N/M Margins · derivedGross margin28.2%−13.2 pt vs Q3 2022
Operating margin-62.3%−29.3 pt vs Q3 2022
Net margin-65.9%−33.3 pt vs Q3 2022
ended Dec 31, 2022 · filed Feb 14, 2023 · 45 d after period end